Related Experiment Video
Updated: Jun 1, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Analysis of 3,4-methylenedioxymetamphetamine: whole blood versus dried blood spots
Ricarda Jantos1, Janet L Veldstra, Rainer Mattern
1Institute of Legal Medicine and Traffic Medicine, University Hospital, Heidelberg, Germany. ricarda.jantos@med.uni-heidelberg.de
Abstract:
Analysis of dried blood spots is an increasingly accepted method in therapeutic drug monitoring, whereas its application by analogy to forensic samples has not been studied in detail. Therefore, we investigated whether determination of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolite 3,4-methylendioxyamphetamine (MDA) from dried blood spots (DBS) is as reliable as that from whole blood specimens. Analysis was performed by liquid chromatography-tandem mass spectrometry following liquid-liquid extraction of blood and corresponding DBS samples from 20 volunteers participating in a controlled driving experiment under the influence of MDMA. The assay was checked for carryover, ion suppression/enhancement, linearity of response, lower limits of detection (LLOD) and quantitation, extraction efficiency and the within-run and between-run assay imprecision for both whole blood and DBS. The LLODs were 2.0 and 1.6 ng/mL for MDMA in whole blood and DBS, respectively, using a volume of 100 μL. LLODs of MDA were determined to be 0.25 ng/mL in whole blood specimens and 0.12 ng/mL in DBS. Extraction efficiency and imprecision did not differ significantly between the two methods for both MDMA and MDA. The mean concentration ratio of corresponding whole blood and DBS samples, t-test, and the Bland-Altman difference plot were used to test hypothesis of equality. Statistical analyses revealed that methods did not significantly differ for MDMA or MDA. Thus, DBS analysis has potential as a precise and inexpensive alternative to whole blood analysis of MDMA.
Insights
Dried blood spot analysis offers a reliable method for detecting 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylendioxyamphetamine (MDA) in forensic toxicology. This technique is a precise and cost-effective alternative to traditional whole blood analysis.
Area of Science:
- Forensic Toxicology
- Analytical Chemistry
- Pharmacology
Background:
- Dried blood spot (DBS) analysis is established for therapeutic drug monitoring.
- Its utility in forensic toxicology, particularly for illicit substances like MDMA, requires further investigation.
Purpose of the Study:
- To evaluate the reliability of DBS analysis for quantifying 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylendioxyamphetamine (MDA) compared to whole blood.
- To assess DBS as a viable alternative for forensic drug testing.
Main Methods:
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed for analysis.
- Samples from 20 volunteers in a controlled MDMA driving experiment were analyzed using both whole blood and DBS.
- Assay validation included checks for carryover, ion effects, linearity, limits of detection/quantitation, extraction efficiency, and imprecision.
Main Results:
- Lower limits of detection (LLOD) for MDMA were 2.0 ng/mL (whole blood) and 1.6 ng/mL (DBS).
- LLODs for MDA were 0.25 ng/mL (whole blood) and 0.12 ng/mL (DBS).
- Extraction efficiency and assay imprecision showed no significant differences between whole blood and DBS methods for both analytes. Statistical analysis confirmed no significant method-dependent differences for MDMA or MDA.
Conclusions:
- DBS analysis provides a precise and inexpensive alternative to whole blood analysis for MDMA and MDA.
- This method holds significant potential for application in forensic toxicology and drug monitoring.
